# Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

> **NCT06460844** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ray Therapeutics, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Choroideremia

## Interventions

- **GENETIC:** RTx-015

## Key facts

- **NCT ID:** NCT06460844
- **Lead sponsor:** Ray Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-27
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06460844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06460844, "Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06460844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*